Delmar, a subsidiary of Italy-based Holding Fabbrica Italiana specialized in the production of chemicals for the pharmaceutical industry, will invest $45 million to expand its operations and create a center of excellence for the production of active pharmaceutical ingredients in Montreal, Canada.
The investment project to modernize the facilities and increase the company’s production capacity will include expanding the plant in the Borough of LaSalle and purchasing cutting-edge equipment, according to Montreal International. With the establishment of its centre of excellence, the sole API manufacturer in Quebec will be able to satisfy new market opportunities, for both patented and generic pharmaceutical products.
“As a result of our R&D, and by investing in cutting-edge technology and in our staff, we were able to develop innovative products and double our production capacity. Creating a centre of excellence means we will be strategically positioned in the API industry and win global market shares, which should reach $1.2 billion within five years,” said Luigi Erriquez, General Manager, Delmar Chemicals.
Delmar will be able to focus on research and development, where it already invests nearly half a million dollars every year, working with Université de Montréal, McGill University and UQAM. This collaboration has already resulted in six new generic products in the past two years.